Balanced news tone
News Sentiment
IMNN sentiment intelligence
Imunon Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+5.8% over one week, +0.0% over four weeks, trend inactive, and below fair value.
OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Imunon, Inc. Actuals & Estimates (NASDAQ:IMNN)
This article provides an overview of Imunon, Inc. (NASDAQ:IMNN) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, such as earnings, revenue, net income, and upcoming earnings release d
- Tone
- Negative 35/100
- Event
- Earnings
- Published
- 25 Jun 2026 23:38
- Source
- TradingView
IMNN Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Imunon, Inc. (IMNN) stock, based on analyst opinions. It details the company's current stock performance, historical highs and lows, market capitalization, earnings reports, and technical analysis indicators. The article also
- Tone
- Negative 38/100
- Event
- Analyst action
- Published
- 25 Jun 2026 19:10
- Source
- TradingView
Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 12:48
- Source
- MT Newswires
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 12:00
- Source
- GlobeNewswire
Imunon (IMNN) executive chair granted 4,629 shares in lieu of cash pay
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
IMUNON’s Phase 3 OVATION 3 Trial in Advanced Ovarian Cancer Recommended to Continue by Independent Data Monitoring Committee
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Quiver Quantitative
IMUNON ovarian cancer trial stays on track after safety review
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
Imunon (IMNN) CEO Stacy Lindborg gets 1,803-share stock grant in lieu of salary
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
IMUNON to Present at the Life Sciences Investor Forum on June 25th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:15
- Source
- GlobeNewswire
IMUNON CEO to take live questions June 25 at investor forum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Stock Titan
Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 14:32
- Source
- InvestorsHub
IMUNON Announces Up to $10 Million Cash Financing
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 04 Jun 2026 12:00
- Source
- GlobeNewswire
IMUNON raises $10M after ovarian cancer drug shows 14.7-month gain
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- Stock Titan
Imunon Secures $10 Million Financing From Streeterville Capital; Issues Preferred Stock and Notes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- TradingView
Imunon IMNN Q4 2025 Earnings Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jun 2026 15:47
- Source
- Motley Fool
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
May 12 webcast to cover IMUNON's Q1 results, Phase 3 ovarian cancer update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 May 2026 07:00
- Source
- Stock Titan
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
IMUNON Reports 2025 Financial Results and Provides Business
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 31 Mar 2026 07:00
- Source
- GlobeNewswire
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
IMUNON Reports Updated Phase 2 Data Showing Continued
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- GlobeNewswire
Imunon (IMNN) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Sep 2022 13:23
- Source
- MarketBeat